How effective are clarithromycin extended-release tablets in the treatment of mycoplasma infection

Clarithromycin sustained-release tablets (Moxin) are prescription drugs, developed and produced by Hainan Puli Pharmaceutical Co., Ltd., and have a good effect on the detailed instructions. So how effective are clarithromycin extended-release tablets in the treatment of mycoplasma infection

Mycoplasma, also known as Mycoplasma humanoids, was discovered in 1898 and is a simple prokaryotic organism. Its size is somewhere between bacteria and viruses.

Clarithromycin extended-release tablets are able to treat mycoplasma. The main ingredient of clarithromycin extended-release tablets is clarithromycin, which belongs to the semi-synthetic macrolide antibiotics.Clarithromycin can bind to the 50S subunit of the bacterial ribosome, thereby inhibiting its protein synthesis and producing antibacterial effects. In vitro, it has good antibacterial activity against both standard strains and clinical isolates, and has good antibacterial activity against a variety of aerobic and anaerobic Gram-positive or Gram-negative bacteria.

The antimicrobial effect of clarithromycin is similar to that of erythromycin. Clarithromycin can inhibit Legionella pneumophila and Mycoplasma hominis, kill Helicobacter pylori, Mycobacterium, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and Listeria monocytogenes, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Gonococcus, Legionella pneumophila, Ureaplasma urealyticum, Chlamydia pneumoniae, Mycobacterium leprosy, Mycobacterium kansas, Mycobacterium turtles, Mycobacterium incidentalis, Mycobacterium avium.